Scinovex
articleTop 1% cited

Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration

Ophthalmology · 2006 · Vol. 113(3) · pp. 363–372.e5
Robert L. AveryDante J. PieramiciMelvin RabenaAlessandro CastellarinMa'an NasirMatthew Giust
Retinal Diseases and TreatmentsRetinal Imaging and AnalysisOcular Diseases and Behçet’s SyndromeMedicineMacular degenerationOphthalmologyBevacizumabFluorescein angiographyVisual acuityRetinalMacular edemaPegaptanibSurgery

MeSH terms

BevacizumabAgedAged, 80 and overAntibodies, MonoclonalFemaleFluorescein AngiographyFovea CentralisHumansInjectionsMacular DegenerationMaleMiddle AgedPapilledemaPigment Epithelium of EyeRetina
Citations
1,136
FWCI
135.95
field-weighted impact
References
36
Percentile
100%
vs. same field & year
Citations per year
References
Histology of the Human Eye: An Atlas and Textbook
The Medical Journal of Australia · 1972 · 636 citations
Preclinical Pharmacokinetics of Ranibizumab (rhuFabV2) after a Single Intravitreal Administration
Investigative Ophthalmology & Visual Science · 2005 · 502 citations
Vascular Endothelial Growth Factor
Arteriosclerosis Thrombosis and Vascular Biology · 2009 · 1,271 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.

Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration · Scinovex